Promising new shingles vaccine enters human trials
NCT ID NCT06932523
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new recombinant shingles vaccine in healthy adults aged 40 and above. Researchers will give two doses and monitor for side effects and immune response. The trial involves 645 participants and compares the new vaccine to an existing one (Shingrix) and placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- recombinant herpes zoster vaccine (CHO cells)
- What this could lead to
- If successful, this could provide a new option to prevent shingles in adults 40 and older.
- What could go wrong
- This is an early-phase trial (phase 1/2) with 645 participants, so safety and effectiveness are not yet proven. The vaccine may cause side effects or fail to generate strong immunity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HERPES ZOSTER (HZ) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hubei Provincial Center for Disease Control and Prevention
RECRUITINGWuhan, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.